New drug cocktail targets Hard-to-Treat liver cancer
NCT ID NCT07535840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs—firsekibart, tislelizumab, and lenvatinib—in people with advanced liver cancer that has a specific genetic change called a TP53 mutation. Participants must have already tried immunotherapy without success. The goal is to see if this drug mix can shrink tumors and control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink liver tumors?
- Ancient herbal mix could boost liver health in advanced cancer
- Double immune attack: new drug combo takes on advanced liver cancer
- Breathing pure oxygen during an MRI may reveal whether liver cancer treatment is working
- Radiation and drug combo shows promise for tough liver cancers
- New immunotherapy combo aims to stop liver cancer return after surgery